Dropinski Jerzy, Musial Jacek, Sanak Marek, Wegrzyn Wojciech, Nizankowski Rafal, Szczeklik Andrew
Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland, 31-066 Krakow, ul. Skawinska 8, Poland.
Thromb Res. 2007;119(3):301-3. doi: 10.1016/j.thromres.2006.03.005. Epub 2006 May 3.
The diallelic glycoprotein IIIa polymorphism P1A1/A2 was attributed to be an inherited risk factor for coronary events. Whether this polymorphism affects response to aspirin in patients with coronary artery disease is not known.
We assessed thrombin generation (prothrombin fragment F1+2) in consecutive blood samples collected from bleeding-time wounds in 28 men with coronary artery disease; P1A2 carriers, n=9; P1A1/A1, n=19. Thrombin generation and bleeding time were measured before and after 2 weeks of aspirin 300 mg/day.
Aspirin-depressed thrombin generation in A1 homozygotes (p=0.04), but not in A2 carriers. Bleeding time after aspirin was also prolonged in A1 subjects only (p=0.02).
Genotyping for glycoprotein IIIa polymorphism might be helpful in predicting antithrombotic action of aspirin in secondary prevention of coronary artery disease.
双等位基因糖蛋白IIIa多态性P1A1/A2被认为是冠状动脉事件的一个遗传风险因素。该多态性是否影响冠状动脉疾病患者对阿司匹林的反应尚不清楚。
我们评估了从28名冠状动脉疾病男性患者出血时间伤口采集的连续血样中的凝血酶生成（凝血酶原片段F1+2）；P1A2携带者，n = 9；P1A1/A1，n = 19。在每天服用300 mg阿司匹林2周前后测量凝血酶生成和出血时间。
阿司匹林抑制A1纯合子的凝血酶生成（p = 0.04），但对A2携带者无此作用。仅A1受试者服用阿司匹林后的出血时间也延长（p = 0.02）。
糖蛋白IIIa多态性基因分型可能有助于预测阿司匹林在冠状动脉疾病二级预防中的抗血栓作用。
